Ann: Trading Halt, page-12

Realistically with sustainable revenue streams still a few years away (it was always going to and still will take more than 12 months to get a half decent market penetration with current products), this will have to be a considerable raise to keep on top of their expenditure.

Net spend for FY21 was 8.5m and they only have about 5m in the bank. The increase in commercialised product activities and late-stage clinical trials will only raise the annual spend.

My guess is without a raise of at least 10-15m this round, we’ll see another CR later this FY. The alternative is they start making partnerships to cover costs and boost market sentiment.

I still like their medical pipeline but they need to start sorting this out